The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
July 15th 2022, 5:00pm
Overall 70% of the patients in both PDS with ranibizumab and ranibizumab alone had almost no retinal thickness fluctuations.
July 15th 2022, 10:00am
The phase 3 data presented at the ISTH 2022 Annual Congress show an 86% reduction of treated bleeds in patients with hemophilia A or B with inhibitors.
July 14th 2022, 7:00pm
Real-world patients showed improvement in visual acuity and anatomic parameters, but are still at an early time point in TRUCKEE study.
July 14th 2022, 6:00pm
Evidence of pegcetacoplan treatment effect observed in the distribution of patients across quartiles in both OAKS and DERBY.
July 14th 2022, 5:00pm
Monthly or every other month intravitreal pegcetacoplan reported to be tolerated in DERBY and OAKS trials.
July 14th 2022, 4:00pm
The best overall outcomes were attained in eyes without fluid and ellipsoid zone integrity preservation, investigators said.
July 2nd 2022, 3:00pm
Travis Vandergriff, MD, discusses the unique collaboration with ophthalmologists and urologists in the rare skin condition.
July 2nd 2022, 11:00am
An analysis of PSOARING 1 and 2 data show the topical therapy is efficacious across a wide spectrum of psoriatic disease and patient demographics.
June 30th 2022, 12:30am
An analysis suggests patients on the biologic fared better with adherence and outcomes than those on competitors including adalimumab.
June 27th 2022, 10:00pm